Business Wire

Proton Making H2 From Oilfields, Scaling Way Up

9.6.2021 13:11:00 EEST | Business Wire | Press release

Share

Last weekend Proton Technologies began loading a trailer with compressed hydrogen from its oilfield.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005271/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Proton Technologies Canada Chair and CEO Grant Strem (Photo: Business Wire)

“As we scale up, costs below 25 cents per kg of H2 seem probable,” says Chair and CEO, Grant Strem.

The process involves injecting oxygen and CO2 into old oilfields like the one Proton purchased out of bankruptcy. Large old oilfields usually still have most of their oil when they are abandoned. Like in a car engine, oxidizing hydrocarbons releases energy.

This liberates hydrogen within the oil field. Injecting ion-rich waste streams turns CO2 into carbonate, producing additional hydrogen while leaving the carbon locked solidly underground. “Our hydrogen should ultimately have a carbon intensity far below zero since we can inject huge volumes of CO2 with oxygen,” added Mr. Strem.

“Big old oilfields are generally co-located with big infrastructure such as wells, powerlines, roads, towns, and pipelines, so we can avoid new environmental disturbances and costs compared to many alternatives,” says COO Setayesh Afshordi.

Proton Canada’s goal is to supply 10% of humanity’s total energy by 2040 – requiring almost 10% of Canada’s oil resource, assuming a 50 year production timeline, although some of this is expected to come out of the North Sea. Proton Technologies has sold licences in over 20 countries.

“We plan to scale-up and proliferate quickly as possible because air pollution is a crisis that Proton Technologies expects to help eradicate while crushing the price of energy and making great returns. I don’t believe anyone will cure cancer for example, while air pollution reigns. Although decarbonization carrots and sticks all align with Proton, compared to how we utilize oilfields for energy today it is simply much more efficient to oxidize hydrocarbons in the pressure vessels nature put them in” added Mr. Strem.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ted Flitton
ted@proton.energy
www.proton.energy

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release

Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio

The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release

The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i

Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release

Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release

CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release

Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye